Vasopressin: a novel target for the prevention and retardation of kidney disease? (Q38084471)

28 August 2017

title

Vasopressin: a novel target for the prevention and retardation of kidney disease? (English)

1 reference

28 August 2017

0 references

1 reference

Lise Bankir

1

0 references

author name string

Nadine Bouby

series ordinal

2

1 reference

28 August 2017

Eberhard Ritz

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

26 February 2013

1 reference

Nature Reviews Nephrology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

223-239

1 reference

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Role of vasopressin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Non-peptide arginine-vasopressin antagonists: the vaptans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin: a biomarker of cardiovascular and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Molecular cloning and expression of a rat V1a arginine vasopressin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Molecular cloning of the receptor for human antidiuretic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin and oxytocin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin receptors in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Fluid and nutrient intake and risk of chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plain-water intake and risk of type 2 diabetes in young and middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Low water intake and risk for new-onset hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plasma copeptin and the risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

"Drink at least eight glasses of water a day." Really? Is there scientific evidence for "8 x 8"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

My doctor said I should drink a lot! Recommendations for fluid intake in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cigarette use and cardiovascular risk in chronic kidney disease: an unappreciated modifiable lifestyle risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Alcohol and kidney damage: a Janus-faced relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The diuretic effects of alcohol and caffeine and total water intake misclassification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin antagonists in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cyclic nucleotide signaling in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Emerging therapies for polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

A case for water in the treatment of polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin directly regulates cyst growth in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Water prescription in autosomal dominant polycystic kidney disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Pancreatic vasopressin V1breceptors: characterization in In-R1-G9 cells and localization in human pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Hypermetabolism of fat in V1a vasopressin receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plasma copeptin, a unifying factor behind the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: importance of atrial natriuretic peptide and glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Nighttime blood pressure and nocturnal dipping are associated with daytime urinary sodium excretion in African subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Ethnic differences in urine concentration: possible relationship to blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Pressor hormones in elderly hypertensive persons. Racial differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin, Urine Concentration, and Hypertension: A New Perspective on an Old Story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Regulation of vasopressin action by prostaglandins. Evidence for prostaglandin synthesis in the rabbit cortical collecting tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Regulation of cyclooxygenase expression by vasopressin in rat renal medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Luminal vasopressin modulates transport in the rabbit cortical collecting duct

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin secretion in normotensive black and white men and women on normal and low sodium diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Gender and renal function influence plasma levels of copeptin in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin: Sexual Dimorphism in Secretion, Cardiovascular Actions and Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Association between hypertension and variation in the alpha- and beta-adducin genes in a white population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Mild dehydration impairs cognitive performance and mood of men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Dehydration influences mood and cognition: a plausible hypothesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cognitive performance and dehydration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Mild dehydration affects mood in healthy young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plasma hypertonicity: another marker of frailty?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Impaired cognitive function and mental performance in mild dehydration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Does having a drink help you think? 6-7-Year-old children show improvements in cognitive performance from baseline to test after having a drink of water

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin receptor mutations in nephrogenic diabetes insipidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Phylogenetic study of the arginine-vasotocin/arginine-vasopressin-like immunoreactive system in invertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Identification of a novel receptor for an invertebrate oxytocin/vasopressin superfamily peptide: molecular and functional evolution of the oxytocin/vasopressin superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cloning and identification of an oxytocin/vasopressin-like receptor and its ligand from insects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Evolution of the vasopressin/oxytocin superfamily: characterization of a cDNA encoding a vasopressin-related precursor, preproconopressin, from the mollusc Lymnaea stagnalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Apelin in the control of body fluid homeostasis and cardiovascular functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The importance of thirst in maintenance of fluid balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Human platelet fraction arginine-vasopressin. Potential physiological role

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin: clinical use of a new biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Molecular pharmacology of V1a vasopressin receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin V1a and V1b receptors: from molecules to physiological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Review article: future indications for terlipressin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin and vasopressin antagonists in heart failure and hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Tolvaptan: A New Therapeutic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Adaptation of the rat kidney to altered water intake and urine concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The J-curve revisited: a therapeutic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Impact of solute intake on urine flow and water excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The influence of bodily hydration on the renal concentrating process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Urea and urine concentrating ability: new insights from studies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Essential role of vasopressin-regulated urea transport processes in the mammalian kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plasma Arginine Vasopressin in diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Urine volume and change in estimated GFR in a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Direct and indirect cost of urea excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Level of hydration and renal function in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Angiotensin I-converting enzyme gene polymorphism in a Serbian population: a gender-specific association with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Relation between human vasopressin 1a gene variance, fat intake, and diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

High urine volume and low urine osmolality are risk factors for faster progression of renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Effects of systemic hypertension, antidiuretic hormone, and prostaglandins on remnant nephrons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Adaptation of the kidney to protein intake and to urine concentrating activity: similar consequences in health and CRF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin receptor mRNA expression in the human gastrointestinal tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin promotes the metabolism of near-physiological concentration of glutamine in isolated rat liver cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The effect of vasopressin infusion on glucose metabolism in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Plasma Vasopressin in Uncontrolled Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin and diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Hypertonic cell volume regulation in mouse thick limbs. I. ADH dependency and nephron heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Reduced insulin secretion and nocturnal dipping of blood pressure are associated with a disturbed circadian pattern of urine excretion in metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Association of arginine vasopressin and arterial blood pressure in a population-based sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Role of vasopressin in essential hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Historadioautographic localization of oxytocin and V1a vasopressin binding sites in the kidney of developing and adult rabbit, mouse and merione and of adult human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Natriuretic response of the rat to plasma concentrations of arginine vasopressin within the physiological range

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Cell Ca2+ response to luminal vasopressin in cortical collecting tubule principal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Sex differences in osmotic regulation of AVP and renal sodium handling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Downregulation of Klotho expression by dehydration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Increasing the daily water intake for the prophylactic treatment of headache: a pilot trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Influence of plasma amino acid level on vasopressin secretion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

cAMP immunocytochemistry provides evidence for functional VIP receptors in trachea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Osmotically induced basolateral K+ conductance in turtle colon: lidocaine-induced K+ channel noise.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Influence of the level of hydration on the renal response to a protein meal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

[Familial proximal tubular azotemia. Elevated urea plasma levels in normal kidney function]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Carbamoylation of amino acids and proteins in uremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Inappropriate vasopressin secretion (SIADH) in burned patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Disposal of large urea overloads by the rat kidney: a micropuncture study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.22

Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure

31 March 2020

1 reference

12 December 2020

A decrease in renal medullary tonicity stimulates anion transport in Henle's loop of rat kidneys

1 reference

12 December 2020

Functional evidence for an apical V1 receptor in rabbit cortical collecting duct

1 reference

12 December 2020

The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects

1 reference

12 December 2020

Regulation of plasma vasopressin in insulin-dependent diabetes mellitus

1 reference

12 December 2020

Renal escape from vasopressin: role of pressure diuresis

1 reference

12 December 2020

Antagonists of the antidiuretic activity of vasopressin

1 reference

12 December 2020

Vasopressin and urinary concentrating activity in diabetes mellitus

1 reference

12 December 2020

Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer

1 reference

12 December 2020

Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes

1 reference

12 December 2020

Effect of long- and short-term antidiuretic hormone availability on internephron heterogeneity in the adult rat

1 reference

12 December 2020

Nephron adaptation to renal injury or ablation

1 reference

12 December 2020

Low urine flow reduces the capacity to excrete a sodium load in humans

1 reference

12 December 2020

AVP receptor antagonists as aquaretics: review and assessment of clinical data

1 reference

12 December 2020

Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats.

1 reference

12 December 2020

Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas

1 reference

12 December 2020

The regulation of vasopressin function in health and disease

1 reference

12 December 2020

Vasopressin receptors. A historical survey

1 reference

12 December 2020

Design of neurohypophyseal peptides that exhibit selective agonistic and antagonistic properties

1 reference

12 December 2020

Hydration biomarkers in free-living adults with different levels of habitual fluid consumption.

1 reference

12 December 2020

Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct

1 reference

12 December 2020

Segmental synthesis and actions of prostaglandins along the nephron

1 reference

12 December 2020

Impaired urinary flow rate during the day: a new factor possibly involved in hypertension and in the lack of nocturnal dipping

1 reference

12 December 2020

Polycystic kidney disease: will it become treatable?

1 reference

12 December 2020

Effect of insulin on osmoregulation of vasopressin

1 reference

12 December 2020

Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat

1 reference

12 December 2020

Sex differences in the endocrine predictors of essential hypertension. Vasopressin versus renin

1 reference

12 December 2020

Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans

1 reference

12 December 2020

Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action

1 reference

12 December 2020

Nonoliguric vasopressin oversecretion in severely burned patients

1 reference

12 December 2020

Is the process of urinary urea concentration responsible for a high glomerular filtration rate?

1 reference

12 December 2020

Characterization of vasopressin receptors of rat urinary bladder and spleen

1 reference

12 December 2020

Osmoregulation and control of vasopressin secretion in healthy humans

1 reference

12 December 2020

Neuropsychological performance, postural stability, and symptoms after dehydration.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2013.22

1 reference

28 August 2017

1 reference